Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9640-0
Annals of Surgical Oncology 15:500-507 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coburn, N. G.
Right arrow Articles by Baxter, N. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coburn, N. G.
Right arrow Articles by Baxter, N. N.

Original Article

Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients

Natalie G. Coburn, MD, MPH1, Anand Govindarajan, MD, MSc1, Calvin H. L. Law, MD, MPH1, Ulrich Guller, MD, MHS1, Alex Kiss, PhD2, Jolie Ringash, MD3, Carol J. Swallow, MD, PhD1 and Nancy N. Baxter, MD, PhD1

1 Department of Surgery, University of Toronto, Toronto, Ontario, Canada
2 Department of Research Design and Biostatistics, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
3 Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada

Correspondence: Address correspondence and reprint requests to: Natalie G. Coburn, MD, MPH; E-mail: natalie.coburn{at}sunnybrook.ca

Background: Adjuvant chemoradiotherapy improved survival in patients with resected gastric adenocarcinoma in the Southwest Oncology Group/Intergroup 0116 trial. Our objective was to examine the impact of adjuvant treatment on overall survival (OS) in the general population.

Methods: Patients 18–85 years old who had undergone resection of non-metastatic gastric adenocarcinoma between May 2000 and December 2003, were identified from the Surveillance Epidemiology and End Results (SEER) database. Patients who had received pre-operative irradiation, had unknown stage or radiation status, or had a survival of 3 months or less from the date of diagnosis were excluded. Survival of those who received post-operative irradiation was compared with those who did not; Kaplan-Meier methods and Cox proportional hazards models were used.

Results: Of 4,041 patients, there was improved survival for those receiving adjuvant irradiation for stages III and IVM0, with a median OS of 31 versus 24 months (P = 0.005) and 20 versus 15 months (P < 0.001), respectively, and a trend for improved survival in univariate analysis of stage II (P = 0.0535). In final adjusted analysis, adjuvant irradiation significantly improved OS in stages III (HR: 0.71, P = 0.0007) and IVM0 (HR: 0.66, P < 0.0001). Adjusted analysis using a propensity score suggested that the benefit of adjuvant irradiation was similar in stage-II and -III patients. However, there was no statistical improvement in survival for stage-Ib and -II patients who had received adjuvant irradiation.

Conclusions: In this population-based analysis, adjuvant radiotherapy for stage-III and IVM0 gastric cancer significantly improved OS. Analysis of stage-Ib and -II patients is limited by small numbers, but there may not be the same benefit.

Key Words: Gastric cancer • Adjuvant therapy




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
T. Liakakos and E. Fatourou
Stage-Specific Guided Adjuvant Treatment for Gastric Cancer
Ann. Surg. Oncol., September 1, 2008; 15(9): 2622 - 2623.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.